Sign in
CompletedPhase 2

To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Burkina Faso, Congo - Kinshasa, Côte d’Ivoire, Kenya, Mozambique, Rwanda, and Uganda9 sites in 7 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
254 people enrolled
Started
7 Mar 2022
Ended
20 Aug 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cipargamin
  • IV Artesunate
  • Coartem
Record updated
9 April 2026

Who can take part

Age
6 months to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Cohort 1: Participants aged ≥ 12 years with moderately severe malaria as defined in (prostration and/or repeated vomiting) without presence of other signs of severe malaria (and with high P. falciparum parasitemia (60,000-250,000 parasites per µl); Subsequent Cohorts 2 to 5: Participants diagnosed with severe malaria as defined in modified version of WHO criteria and P. falciparum parasite count of ≥ 5000 per µl; Cohort 2: Participants aged ≥ 12 years; Cohort 3: Participants aged 6 - < 12 years; Cohort 4: Participants aged 2 - < 6 years; Cohort 5: Participants aged ≥ 6 months - < 2 years

Who cannot take part

  • Treatment with quinine or artemisinin derivative or any other antimalarial drug or any antibiotic with known antimalarial activity within 12 hours of screening
  • Known underlying illness, surgical or medical condition, which is not related to ongoing event of severe malaria and which might jeopardize the participant's health in case of participation in the study or which might alter the distribution, metabolism or excretion of study treatment. For example:; neurological or neurodegenerative disorders,; cardiac, renal, or hepatic disease, diabetes,; epilepsy, cerebral palsy,; known or suspected to be HIV-1 positive and/or receiving antiretroviral treatment; malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases; known or suspected cases of active infections or concurrent febrile illness such as TB, Typhoid, COVID-19 etc; Additional exclusion criteria are as follows:
  • Mixed Plasmodium infections
  • ALT > 5 x the upper limit of normal range (ULN), regardless the level of total bilirubin
  • Total bilirubin is > 3 mg/dL
  • Signs/symptoms of severe malnutrition in general accordance with WHO guidelines:; Under 18 years: <-3 Z-scores of WHO growth standard for weight-for-height/length (in children < 5 years) or BMI for age (5-18 years), or very low mid-upper arm circumference (MUAC < 115 mm in children < 12 years, < 160mm 12-18 years), or bilateral pitting edema; Over 18 years: BMI < 16 kg/m2 or MUAC < 160mm or bilateral pitting edema
  • Body weight of < 35 kg or >75 kg
  • Body weight of < 35 kg or >75 kg
  • Participants diagnosed as moderately severe malaria due to repeated vomiting without presence of any of the symptoms of severe malaria
  • Body weight of < 5 kg
  • Participants diagnosed as moderately severe malaria due to repeated vomiting without presence of any of the symptoms of severe malaria

This trial has no sites in United States.

It has sites in 7 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study was to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria.

Read full original descriptionShow less

The study also intended to evaluate clinical treatment success using a novel clinical endpoint for drug development in severe malaria.

Severe malaria is a medical emergency and is affecting primarily young children in Africa. Injectable artesunate is the standard of care for the treatment of severe malaria and is highly efficacious. However, the spread of artemisinin-resistance in Plasmodium falciparum in Asian countries poses a threat for future treatment of patients with this life-threatening disease. To mitigate this risk, there is a need for another drug in malaria-endemic countries. Cipargamin treatment results in rapid clearance of parasites, including artemisinin-resistant parasites.

The 3 groups in the trial

  • IV Cipargamin 20 mgTreatment being tested

    Participants received intravenous cipargamin 20 mg, as a minimum of two doses every 24 hours, not exceeding 3 doses followed by oral medication (Coartem®, twice daily \[b.i.d.\] for 3 days).

    Treatment: Cipargamin and Coartem

  • IV Cipargamin 40 mgTreatment being tested

    Participants received intravenous cipargamin 40 mg, as a minimum of two doses every 24 hours, not exceeding 3 doses followed by oral medication (Coartem®, twice daily \[b.i.d.\] for 3 days).

    Treatment: Cipargamin and Coartem

  • IV ArtesunateExisting treatment, for comparison

    Participants received IV artesunate according to label and followed by oral medication (Coartem® b.i.d. for 3 days).

    Treatment: IV Artesunate and Coartem

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Adaptive, Randomized, Active-controlled, Open-label, Sequential Cohort, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Intravenous Cipargamin (KAE609) in Adult and Pediatric Participants With Severe Plasmodium Falciparum Malaria (KARISMA - KAE609's Role In Severe Malaria)
Record updated
9 April 2026